Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LAILA S AGRAWAL

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1366670234
CMS profile
430632
Location
LOUISVILLE, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$5,396.25

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $5,396.25 3

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $3,191.25 2
PFIZER INC. $2,205.00 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LAILA S AGRAWAL

NPI 1366670234 · CMS profile ID 430632

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

LOUISVILLE, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1366670234?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LAILA S AGRAWAL, NPI 1366670234, CMS profile ID 430632. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1366670234?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). LAILA S AGRAWAL, NPI 1366670234, CMS profile ID 430632. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1366670234?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
LAILA S AGRAWAL, NPI 1366670234, CMS profile ID 430632, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1366670234?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $5,396.25 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $2,205.0012/20/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050594897 CMS
AstraZeneca Pharmaceuticals LP $1,526.2507/13/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016017331 CMS
AstraZeneca Pharmaceuticals LP $1,665.0002/23/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016084359 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $47,929.40 58
PY2020 $15,753.20 40
PY2021 $16,699.42 10
PY2022 $2,906.25 2
PY2023 $5,396.25 3
PY2024 $3,516.62 4
PY2025 $2,813.87 9

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $927,693.15 74
PY2024 Principal investigator $1,814,881.21 79
PY2023 Principal investigator $1,688,310.67 122
PY2022 Principal investigator $787,931.99 29
PY2021 Principal investigator $311,322.64 11
PY2020 Principal investigator $667,594.69 28
PY2019 Principal investigator $32,399.24 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

122 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $277.81 12/31/2023 Non-covered Recipient Entity
NORTON HEALTHCARE, INC
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 991123601
Principal investigator 1 Seagen Inc. $19,595.00 12/19/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826439
Principal investigator 1 Seagen Inc. $58,785.00 12/19/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826449
Principal investigator 1 Seagen Inc. $39,190.00 12/15/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826429
Principal investigator 1 Seagen Inc. $11,971.00 11/29/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826669
Principal investigator 1 Seagen Inc. $6,105.00 11/29/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826679
Principal investigator 1 Seagen Inc. $17,696.00 11/29/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826685
Principal investigator 1 Seagen Inc. $4,872.50 11/21/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826401
Principal investigator 1 Seagen Inc. $9,797.50 11/21/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826411
Principal investigator 1 Seagen Inc. $4,872.50 11/21/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826479
Principal investigator 1 Seagen Inc. $4,872.50 11/21/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826489
Principal investigator 1 Seagen Inc. $4,872.50 11/21/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826499
Principal investigator 1 Seagen Inc. $4,872.50 11/21/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826509
Principal investigator 1 Seagen Inc. $4,872.50 11/21/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826519
Principal investigator 1 Seagen Inc. $4,872.50 11/21/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826529
Principal investigator 1 Seagen Inc. $4,872.50 11/21/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826539
Principal investigator 1 Seagen Inc. $9,797.50 11/21/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826549
Principal investigator 1 Seagen Inc. $4,872.50 11/21/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826557
Principal investigator 1 Seagen Inc. $4,872.50 11/21/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826565
Principal investigator 1 Seagen Inc. $4,872.50 11/21/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826575
Principal investigator 1 Seagen Inc. $4,872.50 11/21/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826585
Principal investigator 1 Seagen Inc. $9,797.50 11/21/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826595
Principal investigator 1 Seagen Inc. $9,797.50 11/21/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826603
Principal investigator 1 Daiichi Sankyo Inc. $150.00 11/09/2023 Covered Recipient Teaching Hospital
Norton Hospitals Inc
DS-8201-A-U105 No dispute reported 06/30/2026 994244561
Principal investigator 1 Daiichi Sankyo Inc. $4,521.00 11/09/2023 Covered Recipient Teaching Hospital
Norton Hospitals Inc
DS-8201-A-U105 No dispute reported 06/30/2026 994244571
Principal investigator 1 Seagen Inc. $149,630.28 11/08/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826631
Principal investigator 1 AstraZeneca UK Limited $17,662.00 11/07/2023 Non-covered Recipient Entity
NORTON HEALTHCARE, INC
CAMBRIA1 A Phase III, OpenLabel,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant AZD9833,a Next Generation, Oral Selective Estrogen Receptor Degrader vs Standard Endocrine Therapy Aromatase Inhibitor or Tamoxifen in Patients with ER HER2 Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrin Based Therapy Without Disease Recurrence No dispute reported 06/30/2026 991129095
Principal investigator 1 Seagen Inc. $58,785.00 11/02/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826391
Principal investigator 1 PFIZER INC. $7,752.00 10/27/2023 Non-covered Recipient Entity
Norton Healthcare Inc
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1045990149
Principal investigator 1 Seagen Inc. $9,797.50 10/17/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825520
Principal investigator 1 Seagen Inc. $9,797.50 10/17/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825529
Principal investigator 1 Seagen Inc. $9,797.50 10/17/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825539
Principal investigator 1 Seagen Inc. $9,797.50 10/17/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825549
Principal investigator 1 Seagen Inc. $9,797.50 10/17/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825559
Principal investigator 1 Seagen Inc. $9,797.50 10/17/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826469
Principal investigator 1 AstraZeneca Pharmaceuticals LP $21,706.00 10/13/2023 Non-covered Recipient Entity
NORTON HEALTHCARE, INC
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 991139537
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,577.10 10/10/2023 Non-covered Recipient Entity
NORTON CHILDRENS PREVENTION AND WELLNESS
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1017211073
Principal investigator 1 Seagen Inc. $16,999.00 10/04/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826639
Principal investigator 1 Seagen Inc. $6,579.00 10/04/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826649
Principal investigator 1 Seagen Inc. $7,304.00 10/04/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826659
Principal investigator 1 Seagen Inc. $19,595.00 10/03/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825509
Principal investigator 1 Seagen Inc. $19,595.00 09/20/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825629
Principal investigator 1 Seagen Inc. $15,645.00 09/06/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826311
Principal investigator 1 Seagen Inc. $4,070.00 09/06/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826321
Principal investigator 1 Seagen Inc. $6,444.00 09/06/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826331
Principal investigator 1 Seagen Inc. $58,785.00 09/02/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825659
Principal investigator 1 Seagen Inc. $58,785.00 08/23/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825699
Principal investigator 1 Seagen Inc. $58,785.00 08/11/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825679
Principal investigator 1 Seagen Inc. $28,668.74 08/09/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826291
Principal investigator 1 Seagen Inc. $12,135.37 08/09/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826299
Principal investigator 1 Seagen Inc. $4,872.50 07/18/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825649
Principal investigator 1 Seagen Inc. $19,595.00 07/18/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825689
Principal investigator 1 Seagen Inc. $4,872.50 07/18/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825709
Principal investigator 1 Seagen Inc. $4,872.50 07/18/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825719
Principal investigator 1 Seagen Inc. $4,872.50 07/18/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825731
Principal investigator 1 Seagen Inc. $4,872.50 07/18/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825743
Principal investigator 1 Seagen Inc. $4,872.50 07/18/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825751
Principal investigator 1 Seagen Inc. $19,595.00 07/18/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825761
Principal investigator 1 PFIZER INC. $16,913.00 07/08/2023 Non-covered Recipient Entity
Norton Healthcare Inc
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1046113159
Principal investigator 1 Seagen Inc. $58,785.00 07/01/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825669
Principal investigator 1 Seagen Inc. $19,595.00 06/29/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825299
Principal investigator 1 Seagen Inc. $2,035.00 06/28/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825933
Principal investigator 1 Seagen Inc. $4,000.00 06/28/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825945
Principal investigator 1 Seagen Inc. $2,120.00 06/28/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825957
Principal investigator 1 Seagen Inc. $2,382.00 06/28/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825967
Principal investigator 1 Seagen Inc. $2,204.00 06/28/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825977
Principal investigator 1 Seagen Inc. $2,942.00 06/28/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825987
Principal investigator 1 Seagen Inc. $2,035.00 06/28/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826233
Principal investigator 1 Seagen Inc. $4,000.00 06/28/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826243
Principal investigator 1 Seagen Inc. $2,035.00 06/28/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826251
Principal investigator 1 Seagen Inc. $2,120.00 06/28/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826261
Principal investigator 1 Seagen Inc. $2,035.00 06/14/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825873
Principal investigator 1 Seagen Inc. $2,120.00 06/14/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825883
Principal investigator 1 Seagen Inc. $4,000.00 06/14/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825893
Principal investigator 1 Seagen Inc. $2,204.00 06/14/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825903
Principal investigator 1 Seagen Inc. $2,942.00 06/14/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825913
Principal investigator 1 Seagen Inc. $2,382.00 06/14/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825923
Principal investigator 1 Seagen Inc. $2,035.00 06/14/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826059
Principal investigator 1 Seagen Inc. $2,035.00 06/14/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826069
Principal investigator 1 Seagen Inc. $2,035.00 06/14/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826079
Principal investigator 1 Seagen Inc. $2,035.00 06/14/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826089
Principal investigator 1 Seagen Inc. $2,035.00 06/14/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826099
Principal investigator 1 Seagen Inc. $2,120.00 06/14/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826109
Principal investigator 1 Seagen Inc. $2,120.00 06/14/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826119
Principal investigator 1 Seagen Inc. $2,120.00 06/14/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826129
Principal investigator 1 Seagen Inc. $4,000.00 06/14/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826139
Principal investigator 1 Seagen Inc. $2,120.00 06/14/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826149
Principal investigator 1 Seagen Inc. $2,382.00 06/14/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826159
Principal investigator 1 Seagen Inc. $2,942.00 06/14/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826171
Principal investigator 1 Seagen Inc. $4,000.00 06/14/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826181
Principal investigator 1 Seagen Inc. $2,120.00 06/14/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826191
Principal investigator 1 Seagen Inc. $2,204.00 06/14/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826201
Principal investigator 1 Seagen Inc. $2,382.00 06/14/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826211
Principal investigator 1 Seagen Inc. $2,942.00 06/14/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995826223
Principal investigator 1 Seagen Inc. $19,595.00 06/08/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825289
Principal investigator 1 Seagen Inc. $600.00 05/24/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825179
Principal investigator 1 Seagen Inc. $2,458.48 05/24/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825863
Principal investigator 1 Seagen Inc. $58,785.00 05/22/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825279
Principal investigator 1 Daiichi Sankyo Inc. $828.00 05/18/2023 Covered Recipient Teaching Hospital
Norton Hospitals Inc
DS-8201-A-U105 No dispute reported 06/30/2026 994244539
Principal investigator 1 Daiichi Sankyo Inc. $600.00 05/18/2023 Covered Recipient Teaching Hospital
Norton Hospitals Inc
DS-8201-A-U105 No dispute reported 06/30/2026 994244551
Principal investigator 1 Daiichi Sankyo Inc. $2,080.28 05/04/2023 Covered Recipient Teaching Hospital
Norton Hospitals Inc
DS-8201-A-U105 No dispute reported 06/30/2026 994244529
Principal investigator 1 Seagen Inc. $58,785.00 04/19/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825259
Principal investigator 1 Seagen Inc. $58,785.00 04/10/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825229
Principal investigator 1 Seagen Inc. $9,797.50 04/05/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825219
Principal investigator 1 Seagen Inc. $9,797.50 04/05/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825309
Principal investigator 1 Seagen Inc. $9,797.50 04/05/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825319
Principal investigator 1 Daiichi Sankyo Inc. $10,469.00 03/23/2023 Covered Recipient Teaching Hospital
Norton Hospitals Inc
DS-8201-A-U105 No dispute reported 06/30/2026 994244519
Principal investigator 1 Seagen Inc. $27,132.26 02/22/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825793
Principal investigator 1 Seagen Inc. $2,382.00 02/22/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825803
Principal investigator 1 Seagen Inc. $2,942.00 02/22/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825813
Principal investigator 1 Seagen Inc. $4,000.00 02/22/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825821
Principal investigator 1 Seagen Inc. $2,120.00 02/22/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825833
Principal investigator 1 Seagen Inc. $2,204.00 02/22/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825843
Principal investigator 1 Novartis Pharmaceuticals Corporation $29,524.07 02/20/2023 Non-covered Recipient Entity
NORTON CHILDRENS PREVENTION AND WELLNESS
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1017210955
Principal investigator 1 Daiichi Sankyo Inc. $2,080.28 02/16/2023 Covered Recipient Teaching Hospital
Norton Hospitals Inc
DS-8201-A-U105 No dispute reported 06/30/2026 994244507
Principal investigator 1 Seagen Inc. $58,785.00 02/16/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825023
Principal investigator 1 Seagen Inc. $58,785.00 02/06/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825035
Principal investigator 1 AstraZeneca Pharmaceuticals LP $762.42 01/20/2023 Non-covered Recipient Entity
NORTON HEALTHCARE, INC
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 991134943
Principal investigator 1 Seagen Inc. $39,190.00 01/19/2023 Non-covered Recipient Entity
NORTON CANCER INSTITUTE
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995825015
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,485.00 01/13/2023 Covered Recipient Teaching Hospital
Norton Hospitals Inc
A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC) No dispute reported 06/30/2026 991133613
Principal investigator 1 AstraZeneca Pharmaceuticals LP $68,760.41 01/06/2023 Non-covered Recipient Entity
NORTON HEALTHCARE, INC
A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11) No dispute reported 06/30/2026 991136165
Principal investigator 1 AstraZeneca Pharmaceuticals LP $13,640.67 01/04/2023 Covered Recipient Teaching Hospital
Norton Hospitals Inc
A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) No dispute reported 06/30/2026 991130867